HeartCore Enterprises, Inc. Form 8-K Summary
Business Context and Reporting Period
HeartCore Enterprises, Inc. filed a Current Report on Form 8-K dated January 10, 2023, with the report signed on January 17, 2023. The filing reports amendments to executive employment agreements under Item 5.02. The company’s common stock trades on the Nasdaq Capital Market under the symbol HTCR.
Key Financial and Compensation Metrics
| Executive | Prior Annual Base Salary | New Annual Base Salary | Increase |
|---|---|---|---|
| Qizhi Gao, Chief Financial Officer | $54,012 | $120,222 | $66,210 |
| Kimio Hosaka, Chief Operating Officer and Director | $95,459 | $164,770 | $69,311 |
| Keisuke Kuno, CX Division Vice President | $109,100 | $152,308 | $43,208 |
| Hidekazu Miyata, Chief Technical Officer | $75,600 | $112,616 | $37,016 |
The salary increases are effective January 1, 2023. The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material Changes Versus the Prior Comparable Period
On January 10, 2023, the company entered into Amendment No. 1 to the employment agreement of each listed executive. Annual base salaries increased by approximately 61% to 123%, depending on the executive. All other provisions of the employment agreements remain in effect.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, management forecast, risk update, contingency disclosure, or unusual operating item. The amendments are executive compensation changes and may increase future compensation expense, but the filing does not quantify the expected total expense or cash impact.
Important Facts to Verify
- Review the complete amendments when they are filed with the company’s next periodic report.
- Verify the effective date and final salary terms in the underlying agreements.
- Assess the effect of the increased executive compensation on future operating expenses and liquidity.
- Review subsequent periodic filings for related-party, compensation, and financial statement disclosures.